Business briefs: HRT, HPV, Novo Nordisk
Fear over adverse reactions is getting between teen girls and HPV vaccinations, Reuters reported Monday. Reuters said a survey by the University of Oklahoma Health Sciences Center found that about 75% of girls between 13 and 17 were either not being vaccinated or not getting the full three-shot regimen. While adverse reactions were cited, the survey also said parents were shunning the shots because doctors did not recommend it, they do not believe their child was is sexually active, and they don't think the shot is necessary. Merck and GSK manufacture the HPV vaccines Gardasil and Cervarix.
Novo Nordisk's latest Phase IIIa liraglutide-obesity trial indicated that obese patients with a mean baseline BMI of 37 lost between 5% and 6% of their weight, compared to the average 2% weight loss on placebo -- a big disappointment for analysts and investors. The weight-loss range was associated with the 1.8mg and 3mg doses of the GLP-1 analogue, respectively. The trial ran for 56 weeks and included 846 overweight or obese type 2 diabetes patients who took the drugs for 56 weeks and were then observed for 12 additional weeks. The trial is one of four SCALE trials, which assess around 5,000 patients who are either overweight with a BMI of at least 27 and a co-morbid condition, like hypertension, or obese, with a BMI of at least 30, with or without a comorbid condition, like type 2 diabetes.